Bone Biologics Corp

For the period ended Jun 30, 2026. Filed Aug 14, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 14, 2026

BBLG$0.34+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Statements of Cash Flows

Condensed Consolidated Statements of Cash Flows

Six months Ended June 30, 2026 · Six months Ended June 30, 2025
(unaudited) · (unaudited)
Cash flows from operating activities
Net loss		$(1,539,690)		$(1,757,611)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		31,758		123,504
Change in fair value of warrant liability		(157)		(2,257)
Changes in operating assets and liabilities:
Advances on research and development contract services		-		49,087
Prepaid insurance		106,682		125,403
Interest receivable		2,909		-
Prepaid financing costs		(52,666)		-
Accounts payable and accrued expenses		128,442		76,870
Net cash used in operating activities		(1,322,722)		(1,385,004)
Cash flows from financing activities
Proceeds from issuance of common shares from ATM, net of costs		20,180		347,549
Proceeds from sale of common stock and warrants in public offering, net of offering costs		-		4,352,792
Net cash provided by financing activities		20,180		4,700,341
Net increase (decrease) in cash		(1,302,542)		3,315,337
Cash, beginning of period		5,334,322		3,325,131
Cash, end of period		$4,031,780		$6,640,468
Supplemental information
Income taxes paid	$	-	$	-
Noncash investing and financing activities
Options issued to settle accrued bonus		$34,854		46,183

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.